Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
News
Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses
The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant….
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
First Immunosynthen ADC product candidate enters the clinic CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE)…
Grace Breeding Study Results of its Proprietary Environment- Friendly Bio-Fertilizer (“NFT”) Show Superior Growth Results in Brazilian Corn, Outperforming Standard Nitrogen Fertilizers While Reducing Carbon Emissions
Final study results show Grace Breeding’s NFT, an alternative to reduce urea, was superior or…
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
Topline results expected in first half of 2023 Trial sites open in Australia and United…
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”),…
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18…
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in…
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”),…
Dante Genomics’ sequencing hub in Dubai receives ISO 15189 Medical Laboratory accreditation to bring clinical whole genome sequencing to the next billion patients
NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics…
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian Disorder…
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of…
First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI)…
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin…
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma BOSTON, Jan….
Infinidat’s InfiniBox SSA II and InfiniGuard Named Gold Winners in TechTarget’s 2022 Product of the Year Awards
WALTHAM, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) — Infinidat, a leading provider of enterprise storage…
Immutable Holdings Provides Update on Coffee and Crypto Daily Newsletter and Launches Accompanying Podcast
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) — Immutable Holdings Inc. (NEO: HOLD; OTC: IHDLF) (“Immutable…
DGTL Holdings Inc. Signs New Advertising Study with Entertainment Development and Production Company
Deep Diagnostics Study Utilizing DGTL’s Flagship PaaS TotalSocial New York, New York–(Newsfile Corp. – January…
Hypercharge to Provide EV Chargers, Including Level 3 DC Fast Charging, to Municipal Properties in Devon, Alberta
The contract includes a local government office, community centre, and arena. Vancouver, British Columbia and…